Sichenzia Ross Friedman Ference LLP Advises Amarantus on $5M PIPE Investment from Discover Growth Fund
New York, NY – April 29, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and orphan diseases, on a $5 million investment from Discover Growth Fund.
Pursuant to the transaction’s Stock Purchase Agreement, Amarantus issued 1,087 shares of designated Series G Preferred stock at a fixed price of $0.06 per share for gross proceeds of $5,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Partner Harvey Kesner Publishes Article on US Regulators’ Struggle to Address Cryptocurrenices, ICOs and STOs - June 22, 2018
- Sichenzia Ross Ference Kesner LLP Represents ThinkEquity, a Division of Fordham Financial Management as Sole Book-Running Manager on $18 Million Public Offering of Securities of Trovagene, Inc. - June 12, 2018
- 33/34 Act, M & A Corporate Associate - June 11, 2018